市場調査レポート
商品コード
1462450

湿疹治療薬の世界市場 2024-2028

Global Eczema Therapeutics Market 2024-2028

出版日: | 発行: TechNavio | ページ情報: 英文 172 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.88円
湿疹治療薬の世界市場 2024-2028
出版日: 2024年04月01日
発行: TechNavio
ページ情報: 英文 172 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

湿疹治療薬市場は2023-2028年に58億1,000万米ドル、予測期間中のCAGRは10.28%で成長すると予測されます。

当レポートでは、湿疹治療薬市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、アトピー性皮膚炎の有病率の高さ、湿疹治療のための製品上市の増加、エンドユーザーにおける市販(OTC)湿疹治療薬の需要増加が牽引しています。

市場範囲
基準年 2024
終了年 2028
予測期間 2024-2028
成長モメンタム 加速
前年比2024年 9.55%
CAGR 10.28%
増分額 58億1,000万米ドル

本調査では、湿疹治療薬における遠隔医療プラットフォームの採用が増加していることが、今後数年間の湿疹治療薬市場成長を牽引する主要因の1つであると分析しています。また、湿疹治療への生物学的療法の採用拡大や、湿疹治療薬の需要を急増させるヘルスケア支出の増加も、市場の大きな需要につながります。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模の評価

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2023
  • 市場の見通し 2023-2028

第4章 市場規模実績

  • 湿疹治療薬の世界市場 2018-2022
  • 用途別セグメント分析 2018-2022
  • 流通チャネルセグメント分析 2018-2022
  • 地域別セグメント分析 2018-2022
  • 国別セグメント分析 2018-2022

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 市場セグメンテーション:用途別

  • 市場セグメント
  • 比較:用途別
  • アトピー性皮膚炎:市場規模と予測 2023-2028
  • 接触性皮膚炎:市場規模と予測 2023-2028
  • その他の適応症:市場規模と予測 2023-2028
  • 市場機会:用途別

第7章 市場セグメンテーション:流通チャネル別

  • 市場セグメント
  • 比較:流通チャネル別
  • 病院と診療所:市場規模と予測 2023-2028
  • オンライン薬局:市場規模と予測 2023-2028
  • 小売薬局:市場規模と予測 2023-2028
  • 市場機会:流通チャネル別

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米:市場規模と予測 2023-2028
  • 欧州:市場規模と予測 2023-2028
  • アジア:市場規模と予測 2023-2028
  • 世界のその他の地域:市場規模と予測 2023-2028
  • 米国:市場規模と予測 2023-2028
  • ドイツ:市場規模と予測 2023-2028
  • 英国:市場規模と予測 2023-2028
  • 中国:市場規模と予測 2023-2028
  • カナダ:市場規模と予測 2023-2028
  • 市場機会:地域情勢別

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • Alliance Pharma PLC
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Cadila Pharmaceuticals Ltd.
  • Eli Lilly and Co.
  • LEO Pharma AS
  • Lupin Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Viatris Inc.

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Application
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
  • Exhibits18: Historic Market Size - Data Table on global eczema therapeutics market 2018 - 2022 ($ billion)
  • Exhibits19: Historic Market Size - Application Segment 2018 - 2022 ($ billion)
  • Exhibits20: Historic Market Size - Distribution channel Segment 2018 - 2022 ($ billion)
  • Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
  • Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
  • Exhibits23: Five forces analysis - Comparison between 2023 and 2028
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
  • Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
  • Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
  • Exhibits29: Chart on Market condition - Five forces 2023 and 2028
  • Exhibits30: Chart on Application - Market share 2023-2028 (%)
  • Exhibits31: Data Table on Application - Market share 2023-2028 (%)
  • Exhibits32: Chart on Comparison by Application
  • Exhibits33: Data Table on Comparison by Application
  • Exhibits34: Chart on Atopic dermatitis - Market size and forecast 2023-2028 ($ billion)
  • Exhibits35: Data Table on Atopic dermatitis - Market size and forecast 2023-2028 ($ billion)
  • Exhibits36: Chart on Atopic dermatitis - Year-over-year growth 2023-2028 (%)
  • Exhibits37: Data Table on Atopic dermatitis - Year-over-year growth 2023-2028 (%)
  • Exhibits38: Chart on Contact dermatitis - Market size and forecast 2023-2028 ($ billion)
  • Exhibits39: Data Table on Contact dermatitis - Market size and forecast 2023-2028 ($ billion)
  • Exhibits40: Chart on Contact dermatitis - Year-over-year growth 2023-2028 (%)
  • Exhibits41: Data Table on Contact dermatitis - Year-over-year growth 2023-2028 (%)
  • Exhibits42: Chart on Other indication - Market size and forecast 2023-2028 ($ billion)
  • Exhibits43: Data Table on Other indication - Market size and forecast 2023-2028 ($ billion)
  • Exhibits44: Chart on Other indication - Year-over-year growth 2023-2028 (%)
  • Exhibits45: Data Table on Other indication - Year-over-year growth 2023-2028 (%)
  • Exhibits46: Market opportunity by Application ($ billion)
  • Exhibits47: Data Table on Market opportunity by Application ($ billion)
  • Exhibits48: Chart on Distribution Channel - Market share 2023-2028 (%)
  • Exhibits49: Data Table on Distribution Channel - Market share 2023-2028 (%)
  • Exhibits50: Chart on Comparison by Distribution Channel
  • Exhibits51: Data Table on Comparison by Distribution Channel
  • Exhibits52: Chart on Hospital and clinics - Market size and forecast 2023-2028 ($ billion)
  • Exhibits53: Data Table on Hospital and clinics - Market size and forecast 2023-2028 ($ billion)
  • Exhibits54: Chart on Hospital and clinics - Year-over-year growth 2023-2028 (%)
  • Exhibits55: Data Table on Hospital and clinics - Year-over-year growth 2023-2028 (%)
  • Exhibits56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
  • Exhibits57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
  • Exhibits58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibits59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibits60: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
  • Exhibits61: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
  • Exhibits62: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibits63: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
  • Exhibits64: Market opportunity by Distribution Channel ($ billion)
  • Exhibits65: Data Table on Market opportunity by Distribution Channel ($ billion)
  • Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits67: Chart on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibits68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
  • Exhibits69: Chart on Geographic comparison
  • Exhibits70: Data Table on Geographic comparison
  • Exhibits71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibits72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
  • Exhibits73: Chart on North America - Year-over-year growth 2023-2028 (%)
  • Exhibits74: Data Table on North America - Year-over-year growth 2023-2028 (%)
  • Exhibits75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibits76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
  • Exhibits77: Chart on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibits78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • Exhibits79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibits80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
  • Exhibits81: Chart on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibits82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
  • Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • Exhibits87: Chart on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibits88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibits89: Chart on US - Year-over-year growth 2023-2028 (%)
  • Exhibits90: Data Table on US - Year-over-year growth 2023-2028 (%)
  • Exhibits91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibits92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
  • Exhibits93: Chart on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibits94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • Exhibits95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibits96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
  • Exhibits97: Chart on UK - Year-over-year growth 2023-2028 (%)
  • Exhibits98: Data Table on UK - Year-over-year growth 2023-2028 (%)
  • Exhibits99: Chart on China - Market size and forecast 2023-2028 ($ billion)
  • Exhibits100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
  • Exhibits101: Chart on China - Year-over-year growth 2023-2028 (%)
  • Exhibits102: Data Table on China - Year-over-year growth 2023-2028 (%)
  • Exhibits103: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
  • Exhibits104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
  • Exhibits105: Chart on Canada - Year-over-year growth 2023-2028 (%)
  • Exhibits106: Data Table on Canada - Year-over-year growth 2023-2028 (%)
  • Exhibits107: Market opportunity By Geographical Landscape ($ billion)
  • Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ billion)
  • Exhibits109: Impact of drivers and challenges in 2023 and 2028
  • Exhibits110: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits111: Overview on factors of disruption
  • Exhibits112: Impact of key risks on business
  • Exhibits113: Vendors covered
  • Exhibits114: Matrix on vendor position and classification
  • Exhibits115: AbbVie Inc. - Overview
  • Exhibits116: AbbVie Inc. - Product / Service
  • Exhibits117: AbbVie Inc. - Key news
  • Exhibits118: AbbVie Inc. - Key offerings
  • Exhibits119: Alliance Pharma PLC - Overview
  • Exhibits120: Alliance Pharma PLC - Business segments
  • Exhibits121: Alliance Pharma PLC - Key offerings
  • Exhibits122: Alliance Pharma PLC - Segment focus
  • Exhibits123: Amneal Pharmaceuticals Inc. - Overview
  • Exhibits124: Amneal Pharmaceuticals Inc. - Business segments
  • Exhibits125: Amneal Pharmaceuticals Inc. - Key news
  • Exhibits126: Amneal Pharmaceuticals Inc. - Key offerings
  • Exhibits127: Amneal Pharmaceuticals Inc. - Segment focus
  • Exhibits128: AstraZeneca PLC - Overview
  • Exhibits129: AstraZeneca PLC - Product / Service
  • Exhibits130: AstraZeneca PLC - Key news
  • Exhibits131: AstraZeneca PLC - Key offerings
  • Exhibits132: Bausch Health Companies Inc. - Overview
  • Exhibits133: Bausch Health Companies Inc. - Business segments
  • Exhibits134: Bausch Health Companies Inc. - Key news
  • Exhibits135: Bausch Health Companies Inc. - Key offerings
  • Exhibits136: Bausch Health Companies Inc. - Segment focus
  • Exhibits137: Bayer AG - Overview
  • Exhibits138: Bayer AG - Business segments
  • Exhibits139: Bayer AG - Key news
  • Exhibits140: Bayer AG - Key offerings
  • Exhibits141: Bayer AG - Segment focus
  • Exhibits142: Cadila Pharmaceuticals Ltd. - Overview
  • Exhibits143: Cadila Pharmaceuticals Ltd. - Product / Service
  • Exhibits144: Cadila Pharmaceuticals Ltd. - Key news
  • Exhibits145: Cadila Pharmaceuticals Ltd. - Key offerings
  • Exhibits146: Eli Lilly and Co. - Overview
  • Exhibits147: Eli Lilly and Co. - Product / Service
  • Exhibits148: Eli Lilly and Co. - Key news
  • Exhibits149: Eli Lilly and Co. - Key offerings
  • Exhibits150: LEO Pharma AS - Overview
  • Exhibits151: LEO Pharma AS - Business segments
  • Exhibits152: LEO Pharma AS - Key offerings
  • Exhibits153: LEO Pharma AS - Segment focus
  • Exhibits154: Lupin Ltd. - Overview
  • Exhibits155: Lupin Ltd. - Product / Service
  • Exhibits156: Lupin Ltd. - Key news
  • Exhibits157: Lupin Ltd. - Key offerings
  • Exhibits158: Merck and Co. Inc. - Overview
  • Exhibits159: Merck and Co. Inc. - Business segments
  • Exhibits160: Merck and Co. Inc. - Key news
  • Exhibits161: Merck and Co. Inc. - Key offerings
  • Exhibits162: Merck and Co. Inc. - Segment focus
  • Exhibits163: Novartis AG - Overview
  • Exhibits164: Novartis AG - Business segments
  • Exhibits165: Novartis AG - Key news
  • Exhibits166: Novartis AG - Key offerings
  • Exhibits167: Novartis AG - Segment focus
  • Exhibits168: Pfizer Inc. - Overview
  • Exhibits169: Pfizer Inc. - Product / Service
  • Exhibits170: Pfizer Inc. - Key news
  • Exhibits171: Pfizer Inc. - Key offerings
  • Exhibits172: Sanofi SA - Overview
  • Exhibits173: Sanofi SA - Business segments
  • Exhibits174: Sanofi SA - Key news
  • Exhibits175: Sanofi SA - Key offerings
  • Exhibits176: Sanofi SA - Segment focus
  • Exhibits177: Viatris Inc. - Overview
  • Exhibits178: Viatris Inc. - Business segments
  • Exhibits179: Viatris Inc. - Key news
  • Exhibits180: Viatris Inc. - Key offerings
  • Exhibits181: Viatris Inc. - Segment focus
  • Exhibits182: Inclusions checklist
  • Exhibits183: Exclusions checklist
  • Exhibits184: Currency conversion rates for US$
  • Exhibits185: Research methodology
  • Exhibits186: Validation techniques employed for market sizing
  • Exhibits187: Information sources
  • Exhibits188: List of abbreviations
目次
Product Code: IRTNTR40707

The eczema therapeutics market is forecasted to grow by USD 5.81 bn during 2023-2028, accelerating at a CAGR of 10.28% during the forecast period. The report on the eczema therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of atopic dermatitis, increasing product launches for treating eczema, and increase in demand for over-the-counter (OTC) eczema drugs among end-users.

Technavio's eczema therapeutics market is segmented as below:

Market Scope
Base Year2024
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20249.55%
CAGR10.28%
Incremental Value$5.81bn

By Application

  • Atopic dermatitis
  • Contact dermatitis
  • Other indication

By Distribution Channel

  • Hospital and clinics
  • Online pharmacies
  • Retail pharmacies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the rising adoption of telemedicine platforms in eczema therapeutics as one of the prime reasons driving the eczema therapeutics market growth during the next few years. Also, growing adoption of biologic therapies for eczema treatment and increasing healthcare expenditure surging demand for eczema therapeutics will lead to sizable demand in the market.

The report on the eczema therapeutics market covers the following areas:

  • Eczema therapeutics market sizing
  • Eczema therapeutics market forecast
  • Eczema therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading eczema therapeutics market vendors that include AbbVie Inc., Alliance Pharma PLC, Amneal Pharmaceuticals Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd., Eli Lilly and Co., Incyte Corp., LEO Pharma AS, Lupin Ltd., Mayo Clinic, Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the eczema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview

2 Market Landscape

  • 2.1 Market ecosystem

3 Market Sizing

  • 3.1 Market definition
  • 3.2 Market segment analysis
  • 3.3 Market size 2023
  • 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

  • 4.1 Global eczema therapeutics market 2018 - 2022
  • 4.2 Application Segment Analysis 2018 - 2022
  • 4.3 Distribution channel Segment Analysis 2018 - 2022
  • 4.4 Geography Segment Analysis 2018 - 2022
  • 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

  • 5.1 Five forces summary
  • 5.2 Bargaining power of buyers
  • 5.3 Bargaining power of suppliers
  • 5.4 Threat of new entrants
  • 5.5 Threat of substitutes
  • 5.6 Threat of rivalry
  • 5.7 Market condition

6 Market Segmentation by Application

  • 6.1 Market segments
  • 6.2 Comparison by Application
  • 6.3 Atopic dermatitis - Market size and forecast 2023-2028
  • 6.4 Contact dermatitis - Market size and forecast 2023-2028
  • 6.5 Other indication - Market size and forecast 2023-2028
  • 6.6 Market opportunity by Application

7 Market Segmentation by Distribution Channel

  • 7.1 Market segments
  • 7.2 Comparison by Distribution Channel
  • 7.3 Hospital and clinics - Market size and forecast 2023-2028
  • 7.4 Online pharmacies - Market size and forecast 2023-2028
  • 7.5 Retail pharmacies - Market size and forecast 2023-2028
  • 7.6 Market opportunity by Distribution Channel

8 Customer Landscape

  • 8.1 Customer landscape overview

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • 9.2 Geographic comparison
  • 9.3 North America - Market size and forecast 2023-2028
  • 9.4 Europe - Market size and forecast 2023-2028
  • 9.5 Asia - Market size and forecast 2023-2028
  • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
  • 9.7 US - Market size and forecast 2023-2028
  • 9.8 Germany - Market size and forecast 2023-2028
  • 9.9 UK - Market size and forecast 2023-2028
  • 9.10 China - Market size and forecast 2023-2028
  • 9.11 Canada - Market size and forecast 2023-2028
  • 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • 11.3 Landscape disruption
  • 11.4 Industry risks

12 Vendor Analysis

  • 12.1 Vendors covered
  • 12.2 Market positioning of vendors
  • 12.3 AbbVie Inc.
  • 12.4 Alliance Pharma PLC
  • 12.5 Amneal Pharmaceuticals Inc.
  • 12.6 AstraZeneca PLC
  • 12.7 Bausch Health Companies Inc.
  • 12.8 Bayer AG
  • 12.9 Cadila Pharmaceuticals Ltd.
  • 12.10 Eli Lilly and Co.
  • 12.11 LEO Pharma AS
  • 12.12 Lupin Ltd.
  • 12.13 Merck and Co. Inc.
  • 12.14 Novartis AG
  • 12.15 Pfizer Inc.
  • 12.16 Sanofi SA
  • 12.17 Viatris Inc.

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • 13.3 Currency conversion rates for US$
  • 13.4 Research methodology
  • 13.5 List of abbreviations